Gene editing · Gene editing: angiopoietin-like 3 (ANGPTL3) · developed by CRISPR Therapeutics
CTX310 is a lipid nanoparticle formulation of CRISPR-associated protein 9 (Cas9) components for in vivo editing of the ANGPTL3 gene. It is being studied in lipid disorders, including hypertriglyceridemia and familial hypercholesterolemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07491172 | Phase 1 | Cardiovascular | Recruiting | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CardiovascularDyslipidemiasHeterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)HypercholesterolaemiaHypertriglyceridemiaLipid DisorderMetabolic DiseaseMixed HyperlipemiaSevere Hypertriglyceridemia (sHTG)
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →